A Phase 3, randomised, double-blind, placebo-controlled, event-driven study to demonstrate the efficacy and safety of Milvexian, an Oral Factor XIa Inhibitor, after a recent acute coronary syndrome. (LIBREXIA-ACS).
“A Phase 3, randomised, double-blind, double-dummy, parallel group, active controlled study to evaluate the efficacy and safety of Milvexian, an Oral Factor Xla Inhibitor, versus Apixaban in participants with Atrial Fibrillation (LIBREXIA-AF)”
“HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation (EX6018-4915)”
A multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%)
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA)